Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.
Student Research Committee, Faculty of Public Health Branch, Iran University of Medical Sciences, Tehran, Iran.
BMC Complement Med Ther. 2023 Feb 14;23(1):46. doi: 10.1186/s12906-023-03878-0.
Previous studies have shown that Rheum ribes (R. ribes) could be effective in controlling the blood glucose levels. This study was conducted to determine the effects of R. ribes supplementation on glycemic indices and apolipoproteins in patients with type 2 diabetes mellitus (T2DM).
In the present randomized double-blind controlled trial, 60 type 2 diabetic patients aged 30-60 years with a body mass index (BMI) of 20-30 kg/m and hemoglobin A1c (HbA1c) of 6-8% were enrolled. Patients were randomly assigned to receive 450 mg of aqueous R. ribes extract (AG), 450 mg of ethanolic R. ribes extract (EG), or placebo (PG) three times daily for 6 weeks. At the baseline and at the end of the study, blood glucose levels, homeostatic model assessment of insulin resistance (HOMA-IR) and the homeostatic model assessment of β-cell dysfunction (HOMA-B), as well as apolipoprotein A-I (ApoA1) and apolipoprotein B (ApoB) were measured.
There was a significant decrease in the serum levels of insulin in AG and EG groups (P = 0.003 and P = 0.001, respectively), HOMA-IR (P = 0.01 and P = 0.001, respectively), HOMA-B (P = 0.002 and P = 0.001, respectively), ApoB (P = 0.006 and P = 0.03, respectively), ApoB/ApoA1 ratio (P = 0.016 and P = 0.04, respectively). However, a significant increase in ApoA1 (P = 0.08 and P = 0.05, respectively) with no significant changes in blood glucose, at the end of study compared to beginning values, were observed. None of the variables showed a significant change in PG. At the end of the study; while there were significant differences in insulin (P = 0.04), HOMA-IR (P = 0.03), HOMA-B (P = 0.01), ApoB (P = 0.02), and ApoB/ApoA1 ratio (P = 0.03) among the groups but ApoA1 had no significant change.
Consumption of R. ribes intake could have beneficial effects on insulin resistance and apolipoproteins in type 2 diabetic patients. (Registered at en.irct.ir, identification number: IRCT201410142709N31).
先前的研究表明,酸模(Rheum ribes)可以有效控制血糖水平。本研究旨在确定酸模补充剂对 2 型糖尿病(T2DM)患者血糖指数和载脂蛋白的影响。
在这项随机双盲对照试验中,纳入了 60 名年龄在 30-60 岁、BMI 为 20-30kg/m²和糖化血红蛋白(HbA1c)为 6-8%的 2 型糖尿病患者。患者被随机分配接受 450mg 水提酸模提取物(AG)、450mg 醇提酸模提取物(EG)或安慰剂(PG),每日 3 次,持续 6 周。在基线和研究结束时,测量血糖水平、稳态模型评估的胰岛素抵抗(HOMA-IR)和β细胞功能障碍的稳态模型评估(HOMA-B)以及载脂蛋白 A-I(ApoA1)和载脂蛋白 B(ApoB)。
AG 和 EG 组的血清胰岛素水平显著下降(P=0.003 和 P=0.001),HOMA-IR(P=0.01 和 P=0.001)、HOMA-B(P=0.002 和 P=0.001)、ApoB(P=0.006 和 P=0.03)、ApoB/ApoA1 比值(P=0.016 和 P=0.04)也显著下降。然而,与研究开始时相比,研究结束时 ApoA1 显著增加(P=0.08 和 P=0.05),血糖无显著变化。PG 组的所有变量均无显著变化。研究结束时,各组胰岛素(P=0.04)、HOMA-IR(P=0.03)、HOMA-B(P=0.01)、ApoB(P=0.02)和 ApoB/ApoA1 比值(P=0.03)均有显著差异,但 ApoA1 无显著变化。
酸模摄入可能对 2 型糖尿病患者的胰岛素抵抗和载脂蛋白产生有益影响。(在 en.irct.ir 注册,注册号:IRCT201410142709N31)。